Lactococcus lactis CNCM I‐5388 versus NCDO2118 by its GABA hyperproduction ability, counteracts faster stress‐induced intestinal hypersensitivity in rats - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles FASEB Journal Year : 2023

Lactococcus lactis CNCM I‐5388 versus NCDO2118 by its GABA hyperproduction ability, counteracts faster stress‐induced intestinal hypersensitivity in rats

Pedro Gomes
Valérie Laroute
Catherine Beaufrand
  • Function : Author
  • PersonId : 1206468
Nathalie Aubry
Chloé Liebgott
Nathalie Ballet
Sophie Legrain-Raspaud
Vassilia Théodorou
  • Function : Author
  • PersonId : 1216037
Muriel Mercier-Bonin
Connectez-vous pour contacter l'auteur

Abstract

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by its main symptom, visceral hypersensitivity (VH), which is aggravated by stress. Gut–brain interactions and gut bacteria may alleviate IBS symptoms, including VH. γ‐amino butyric acid (GABA), produced notably by lactic acid bacteria (LAB), shows promising result in IBS symptoms treatment. In bacteria, GABA is generated through glutamate decarboxylase (GAD) metabolism of L‐glutamic acid, maintaining intracellular pH. In mammals, GABA acts as an inhibitory neurotransmitter, modulating pain, stress, and anxiety. Therefore, utilizing GABA‐producing LAB as a therapeutic approach might be beneficial. Our previous work showed that a GABA‐producing Lactococcus lactis strain, NCDO2118, reduced VH induced by acute stress in rats after a 10‐day oral treatment. Here, we identified the strain CNCM I‐5388, with a four‐fold higher GABA production rate under the same conditions as NCDO2118. Both strains shared 99.1% identical GAD amino acid sequences and in vitro analyses revealed the same optimal pH for GAD activity; however, CNCM I‐5388 exhibited 17 times higher intracellular GAD activity and increased resistance to acidic pH. Additionally, in vivo experiments have demonstrated that CNCM I‐5388 has faster anti‐VH properties in rats compared with NCDO2118, starting from the fifth day of treatment. Finally, CNCM I‐5388 anti‐VH effects partially persisted after 5‐day treatment interruption and after a single oral treatment. These findings highlight CNCM I‐5388 as a potential therapeutic agent for managing VH in IBS patients.
Fichier principal
Vignette du fichier
The FASEB Journal - 2023 - Gomes - Lactococcus lactis CNCM I‐5388 versus NCDO2118 by its GABA hyperproduction ability .pdf (1.43 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY - Attribution

Dates and versions

hal-04388025 , version 1 (11-01-2024)

Licence

Attribution

Identifiers

Cite

Pedro Gomes, Valérie Laroute, Catherine Beaufrand, Marie-Line Daveran Mingot, Nathalie Aubry, et al.. Lactococcus lactis CNCM I‐5388 versus NCDO2118 by its GABA hyperproduction ability, counteracts faster stress‐induced intestinal hypersensitivity in rats. FASEB Journal, 2023, 37 (11), pp.e23264. ⟨10.1096/fj.202301588R⟩. ⟨hal-04388025⟩
20 View
1 Download

Altmetric

Share

Gmail Facebook X LinkedIn More